The user testing procedure includes a baseline breath sample prior to the subject smoking cannabis followed by samples taken after smoking cannabis at multiple time points up to a minimum of 2 hours.  Newly available images show how a subject interacts with the device at various stages of use. The testing process includes a sampling stage, an analysis stage, and the results stage - showing when THC is detected (a positive result) and when THC is not detected (a negative result).

The THCBA incorporates microfluidic sensor technology for the detection of THC from breath. The Company has been developing the THCBA with Dr. Mina Hoorfar at University of British Columbia Okanagan campus (“UBC”) and has an exclusive technology license agreement with UBC. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of 9-tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment.

About Cannabix Technologies Inc.